Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

42.74 -6.24 (-12.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunocore Holdings Plc ADR

< Previous 1 2 Next >
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presented two posters at CROI 2024
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Prices Upsized Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces upcoming presentation and posters at ESMO 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Institutions are Buying These 3 Stocks and Analysts Agree
Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities. 
Via MarketBeat
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
From Immunocore Holdings Limited
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.